Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.36 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24726507 | 1.00 | TRPA1 (0.45) | TRPA1EGLN2ARTTKMAPKAPK2 | |
| SCHEMBL30929464 | 0.85 | EGLN2 (0.41) | TRPA1EGLN2ARTTKMAPKAPK2 | |
| SCHEMBL7001261 | 0.85 | EGLN2 (0.41) | TRPA1EGLN2ARTTKMAPKAPK2 | |
| SCHEMBL7310686 | 0.83 | MAPKAPK2 (0.40) | TRPA1EGLN2ARTTKMAPKAPK2 | |
| SCHEMBL24968843 | 0.80 | GSK3B (0.39) | GSK3BDYRK1A | |
| SCHEMBL7106252 | 0.80 | TRPA1 (0.39) | TRPA1EGLN2ARTTKMAPKAPK2 | |
| SCHEMBL24427233 | 0.79 | ATR (0.39) | GSK3BDYRK1A | |
| SCHEMBL21566100 | 0.79 | GSK3B (0.40) | GSK3BDYRK1A | |
| SCHEMBL30075068 | 0.79 | GSK3B (0.40) | GSK3BDYRK1A | |
| SCHEMBL19457874 | 0.78 | ADORA3 (0.39) | GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230138003-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-11566027-B2 | Dihydroindolizinone derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-01-31 | — | — | US | disclosed |
| EP-3702357-B1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2022-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230138003-A1 | DIHYDROINDOLIZINONE DERIVATIVE | TFPI, F2, TFPI2 | TRPA1 3231/4885EGLN2 158/4885AR 4065/4885 |
| US-11566027-B2 | Dihydroindolizinone derivative | CYP2C19, CYP4A22, CYP4A11 | TRPA1 3003/4885EGLN2 271/4885AR 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.